Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
- PMID: 28672011
- PMCID: PMC5495392
- DOI: 10.1371/journal.pone.0180408
Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
Abstract
Background: Various noninvasive liver reserve markers were proposed to indicate the severity of liver damage. However, the role and feasibility of these markers to predict the prognosis of patients with hepatocellular carcinoma (HCC) are unknown. We aimed to identify the prognostic role of the 8 currently used hepatic reserve markers in patients with HCC undergoing transarterial chemoembolization (TACE).
Methods: Between 2002 and 2013, a total of 881 patients with HCC undergoing TACE were prospectively identified and retrospectively analyzed. The baseline characteristics, tumor status and noninvasive markers were collected. Homogeneity and corrected Akaike information criteria (AICc) were compared between these markers. The Cox proportional hazards model was used to identify independent predictors of survival.
Results: Significant differences in survival distribution were found for albumin-bilirubin (ALBI) grade, Child-Turcotte-Pugh (CTP) class, Lok index, fibrosis index based on 4 factors (FIB-4), Göteborg University cirrhosis index (GUCI), cirrhosis discriminant index (CDI) and model for end-stage liver disease (MELD) score (all p values <0.05). Among these markers, the ALBI grade showed the highest homogeneity and lowest AICc value, indicating a better prognostic performance. Cox multivariate analysis confirmed that ALBI grade 2, ascites, serum alkaline phosphatase and α-fetoprotein level, tumor diameter, vascular invasion and performance status were significant independent prognostic predictors. The distribution of the ALBI score well correlated with baseline CTP and MLED scores.
Conclusions: Our data suggest that among the currently used liver reserve markers, ALBI grade may serve as an objective and feasible surrogate to predict the prognosis of HCC patients undergoing TACE.
Conflict of interest statement
Figures



Similar articles
-
Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.BMC Gastroenterol. 2022 Jun 14;22(1):295. doi: 10.1186/s12876-022-02366-y. BMC Gastroenterol. 2022. PMID: 35701739 Free PMC article.
-
Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation.Sci Rep. 2018 Jan 16;8(1):843. doi: 10.1038/s41598-018-19251-y. Sci Rep. 2018. PMID: 29339752 Free PMC article.
-
A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.Liver Int. 2019 Sep;39(9):1704-1712. doi: 10.1111/liv.14194. Epub 2019 Jul 30. Liver Int. 2019. PMID: 31319016
-
Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review.World J Gastroenterol. 2020 Sep 7;26(33):5022-5049. doi: 10.3748/wjg.v26.i33.5022. World J Gastroenterol. 2020. PMID: 32952347 Free PMC article.
-
Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients.Liver Cancer. 2019 Oct;8(5):312-325. doi: 10.1159/000494844. Epub 2018 Nov 29. Liver Cancer. 2019. PMID: 31768342 Free PMC article. Review.
Cited by
-
To determine the prognostic value of the albumin-bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma.Gastroenterol Hepatol Bed Bench. 2019 Spring;12(2):110-115. Gastroenterol Hepatol Bed Bench. 2019. PMID: 31191834 Free PMC article.
-
Prognostic value of pretreatment albumin to bilirubin ratio in patients with hepatocellular cancer: A meta-analysis.Medicine (Baltimore). 2019 Jan;98(2):e14027. doi: 10.1097/MD.0000000000014027. Medicine (Baltimore). 2019. PMID: 30633195 Free PMC article.
-
Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.BMC Gastroenterol. 2022 Jun 14;22(1):295. doi: 10.1186/s12876-022-02366-y. BMC Gastroenterol. 2022. PMID: 35701739 Free PMC article.
-
Combination of systemic immune-inflammation index and albumin-bilirubin grade predict prognosis of regorafenib in unresectable hepatocellular carcinoma.Am J Cancer Res. 2023 Jun 15;13(6):2702-2713. eCollection 2023. Am J Cancer Res. 2023. PMID: 37424826 Free PMC article.
-
Development and Assessment of Novel Predictive Nomograms Based on APRI for Hepatitis B Virus-associated Small Solitary Hepatocellular Carcinoma with Stereotactic Body Radiotherapy.J Cancer. 2020 Sep 23;11(22):6642-6652. doi: 10.7150/jca.47291. eCollection 2020. J Cancer. 2020. PMID: 33046985 Free PMC article.
References
-
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65(2):87–108. Epub 2015/02/06. doi: 10.3322/caac.21262 . - DOI - PubMed
-
- El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27. Epub 2011/10/14. doi: 10.1056/NEJMra1001683 . - DOI - PubMed
-
- Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. J Clin Oncol. 2016;34(15):1787–94. doi: 10.1200/JCO.2015.64.7412 . - DOI - PMC - PubMed
-
- Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, You SL, Wang LY, Chen CJ. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology. 2013. August;58(2):546–54. doi: 10.1002/hep.26385 . - DOI - PubMed
-
- Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma—epidemiological trends and risk factors. Dig Dis. 2009;27(2):80–92. Epub 2009/06/24. doi: 10.1159/000218339 . - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous